Published in Acad Med on January 01, 2001
Mentoring faculty in academic medicine. A new paradigm? J Gen Intern Med (2005) 3.29
Mentorship in academic general internal medicine. Results of a survey of mentors. J Gen Intern Med (2005) 1.43
Role of institutional climate in fostering diversity in biomedical research workforce: a case study. Mt Sinai J Med (2012) 1.41
The positive impact of a facilitated peer mentoring program on academic skills of women faculty. BMC Med Educ (2012) 1.17
Mentorship needs at academic institutions in resource-limited settings: a survey at Makerere University College of Health Sciences. BMC Med Educ (2011) 1.15
Program directors' views of the importance and prevalence of mentoring in internal medicine residencies. J Gen Intern Med (2004) 0.95
Career support in medicine - experiences with a mentoring program for junior physicians at a university hospital. Psychosoc Med (2004) 0.89
Gender Disparities in Academic Practice. Plast Reconstr Surg (2015) 0.81
The medical students' perspective of faculty and informal mentors: a questionnaire study. BMC Med Educ (2016) 0.75
Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler (1999) 4.91
Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest (1977) 4.63
COBAS AMPLICOR: fully automated RNA and DNA amplification and detection system for routine diagnostic PCR. Clin Chem (1996) 3.17
Career intentions of medical students trained in six sub-Saharan African countries. Educ Health (Abingdon) (2011) 2.54
Immunoglobulins in multiple sclerosis and infections of the nervous system. Arch Neurol (1971) 2.51
Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet (1996) 2.06
Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N Engl J Med (1988) 2.04
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer (2004) 2.03
Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest (1977) 2.02
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer (2006) 1.96
Macrophage nomenclature: where are we going? J Reticuloendothel Soc (1980) 1.81
Two subsets of dendritic cells are present in human cerebrospinal fluid. Brain (2001) 1.78
[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. Z Gastroenterol (2011) 1.74
Measuring the effects of an international health professions faculty development fellowship: the FAIMER Institute. Med Teach (2010) 1.68
T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis. J Immunol (1991) 1.65
Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis. Eur J Neurol (2000) 1.61
Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J Clin Invest (1990) 1.57
Early diagnosis of tuberculous meningitis by detection of anti-BCG secreting cells in cerebrospinal fluid. Lancet (1990) 1.55
Increased incidence of Guillain-Barré syndrome postpartum. Epidemiology (1998) 1.53
Neutralization of macrophage inflammatory protein 2 (MIP-2) and MIP-1alpha attenuates neutrophil recruitment in the central nervous system during experimental bacterial meningitis. Infect Immun (1999) 1.48
Comparison of antibodies against different viruses in cerebrospinal fluid and serum samples from patients with multiple sclerosis. Infect Immun (1974) 1.48
Altered surface marker expression and function of G-CSF-induced neutrophils from test subjects and patients under chemotherapy. Br J Haematol (1994) 1.45
Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood (1993) 1.45
Measles virus antibodies in multiple sclerosis. Comparison of antibody titers in cerebrospinal fluid and serum. Arch Neurol (1974) 1.44
Cytokine autoantibodies in multiple sclerosis, aseptic meningitis and stroke. Eur J Clin Invest (1998) 1.44
The B cell repertoire in experimental allergic neuritis involves multiple myelin proteins and GM1. J Neurol Sci (1994) 1.43
Comparison of antiviral and antitumor activity of activated macrophages. Cell Immunol (1977) 1.42
Age-related cellular resistance of the chicken embryo to viral infections. I. Interferon and natural resistance to myxoviruses and vesicular stomatitis virus. J Infect Dis (1970) 1.42
Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol (2000) 1.40
Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia. Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Br J Haematol (1996) 1.40
Immunoglobulin abnormalities in multiple sclerosis. Relation to clinical parameters: exacerbations and remissions. Arch Neurol (1973) 1.40
Development of junior faculty's self-efficacy: outcomes of a National Center of Leadership in Academic Medicine. Acad Med (2001) 1.38
Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol (2000) 1.37
Kinetics of changes in peritoneal cell populations following acute inflammation. Cell Immunol (1989) 1.37
Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol (1991) 1.36
Immunoglobulins and measles antibodies in subacute sclerosing panencephalitis. Arch Neurol (1973) 1.35
Macrophage extrinsic antiviral activity during herpes simplex virus infection. J Gen Virol (1980) 1.34
Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis. Ann Neurol (1994) 1.33
Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. Leukemia (2000) 1.31
Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res (1996) 1.30
Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol (2001) 1.30
Cerebrospinal fluid and serum immunoglobulins and antibody titers in mumps meningitis and aseptic meningitis of other etiology. Infect Immun (1978) 1.28
Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology (1998) 1.26
Induction of macrophage-mediated tumor-cell cytotoxicity by pyran copolymer. J Natl Cancer Inst (1974) 1.23
Immunoglobulins and measles antibodies in optic neuritis. N Engl J Med (1973) 1.22
CD16- CD56+ natural killer cells after bone marrow transplantation. Blood (1992) 1.21
Review of the macrophage disappearance reaction. J Leukoc Biol (1995) 1.20
Characterization of antibody activity in oligoclonal immunoglobulin G synthesized within the central nervous system in a patient with tuberculous meningitis. J Clin Microbiol (1981) 1.20
Circulating CD4+CD25+ and CD4+CD25+ T cells in myasthenia gravis and in relation to thymectomy. Scand J Immunol (2004) 1.18
Increased IL-1beta, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study. Stroke (1999) 1.18
Multiple sclerosis: disturbed kappa: lambda chain ratio of immunoglobulin G in cerebrospinal fluid. Clin Exp Immunol (1970) 1.18
Principles of albumin and IgG analyses in neurological disorders. II. Relation of the concentration of the proteins in serum and cerebrospinal fluid. Scand J Clin Lab Invest (1977) 1.17
IgG production within the central nervous system: a critical review of proposed formulae. Ann Neurol (1985) 1.17
Antimyelin basic protein and antimyelin antibody-producing cells in multiple sclerosis. Ann Neurol (1990) 1.17
Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor. J Neuroimmunol (1995) 1.17
Respiratory syncytial virus stimulation of vascular endothelial cell growth Factor/Vascular permeability factor. Am J Respir Cell Mol Biol (2000) 1.17
Comparison of electrophoresis on agar gel and agarose gel in the evaluation of gamma-globulin abnormalities in cerebrospinal fluid and serum in multiple sclerosis. Clin Chim Acta (1973) 1.17
Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases. Clin Immunol Immunopathol (1997) 1.16
Seasonal patterns in optic neuritis and multiple sclerosis: a meta-analysis. J Neurol Sci (2000) 1.16
Viruses and the versatile macrophage. Br Med Bull (1985) 1.15
Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J Neuroimmunol (1993) 1.15
Immunomodulator-induced resistance against herpes simplex virus. Proc Soc Exp Biol Med (1977) 1.14
Changes in macrophage ectoenzymes associated with anti-tumor activity. J Immunol (1980) 1.13
Persistence of tropical ataxic neuropathy in a Nigerian community. J Neurol Neurosurg Psychiatry (2000) 1.13
Age-specific prevalence of antibody to enterotoxigenic Escherichia coli in Ecuadorian and German children. J Infect Dis (1990) 1.12
Improved detection of oligoclonal IgG in cerebrospinal fluid by isoelectric focusing in agarose, double-antibody peroxidase labeling, and avidin-biotin amplification. Clin Chem (1984) 1.12
Immune responses to vaginal or systemic infection of BALB/c mice with herpes simplex virus type 2. J Immunol (1977) 1.12
Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls. J Neuroimmunol (1991) 1.11
Macrophage functions in beige (Chédiak-Higashi syndrome) mice. Cancer Res (1980) 1.11
A school-based Chlamydia control program using DNA amplification technology. Pediatrics (1998) 1.11
Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis. J Neuroimmunol (2001) 1.11
CSF neopterin as marker of disease activity in multiple sclerosis. Acta Neurol Scand (1987) 1.10
Protection from oral herpes simplex virus infection by a nucleic acid-free virus vaccine. Infect Immun (1977) 1.09
A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol (2011) 1.08
Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J Immunol (1999) 1.07
Increased levels of interferon-gamma (IFN-gamma), IL-4 and transforming growth factor-beta (TGF-beta) mRNA expressing blood mononuclear cells in human HIV infection. Clin Exp Immunol (1994) 1.07
Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients. Br J Haematol (1996) 1.07
Myelin antigen reactive T cells in cerebrovascular diseases. Clin Exp Immunol (1992) 1.07
Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: identification of regulatory cells. J Immunol (1999) 1.06
Capacity building in medical education and health outcomes in developing countries: the missing link. Educ Health (Abingdon) (2007) 1.05
Oligoclonal Borrelia burgdorferi-specific IgG antibodies in cerebrospinal fluid in Lyme neuroborreliosis. J Infect Dis (1990) 1.05
Relation between benign course of multiple sclerosis and low-grade humoral immune response in cerebrospinal fluid. J Neurol Neurosurg Psychiatry (1980) 1.05
Increased mRNA expression of IL-6, IL-10, TNF-alpha, and perforin in blood mononuclear cells in human HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.05
Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barré syndrome. J Neuroimmunol (1998) 1.04
An immunogenetic heterogeneity in multiple sclerosis. J Neurol Neurosurg Psychiatry (1992) 1.04
IL-17 and IFN-gamma mRNA expression is increased in the brain and systemically after permanent middle cerebral artery occlusion in the rat. J Neuroimmunol (2001) 1.04
Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study. Cancer (1994) 1.04
HLA haplotypes in families with high frequency of multiple sclerosis. Arch Neurol (1976) 1.04
Repression of interferon action: induced dedifferentiation of embryonic cells. Science (1971) 1.03
Effect of anti-T-cell globulin on GVHD in leukemic patients treated with BMT. Transplant Proc (1981) 1.03
Ischemic stroke is associated with a systemic increase of blood mononuclear cells expressing interleukin-8 mRNA. Stroke (1998) 1.02
Predominance of oligoclonal IgG type lambda in CSF in aseptic meningitis. Arch Neurol (1979) 1.02
Oligoclonal IgG and free chains in multiple sclerosis demonstrated by thin-layer polyacrylamide gel isoelectric focusing and immunofixation. Ann Neurol (1980) 1.02
Mechanisms of recovery from experimental allergic encephalomyelitis induced with myelin basic protein peptide 68-86 in Lewis rats: a role for dendritic cells in inducing apoptosis of CD4+ T cells. J Neuroimmunol (1999) 1.02
Advancing women and closing the leadership gap: the Executive Leadership in Academic Medicine (ELAM) program experience. J Womens Health Gend Based Med (2001) 1.02
Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer (2008) 1.01